MazenNoureddinMDMHSc

Hepatology & Liver Transplantation

Transplant Hepatologist, Houston Methodist Hospital, Director Houston Research Institute

Dr. Noureddin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1155 Dairy Ashford Road
Ste 200
Houston, TX 77079
Phone+1 281-809-3234

Fax+1 281-809-3287

Duke School of MedicineMHSc, Master's Health Sciences in Clinical Research, 2009 - 2018
University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2011 - 2013
Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2009 - 2011
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2005 - 2008
University of Aleppo Faculty of MedicineClass of 2002

PubMed

Early-Onset Gastrointestinal Cancers and Metabolic Risk Factors: Global Trends From the Global Burden of Disease Study 2021.
Pojsakorn Danpanichkul, Kanokphong Suparan, Thanida Auttapracha, Primrose Tothanarungroj, Siwanart Kongarin
Mayo Clinic Proceedings. 2025-02-10
Alcohol-related liver and extrahepatic malignancies: burden of disease and socioeconomic disparities in 2019.
Pojsakorn Danpanichkul, Kanokphong Suparan, Nathorn Chaiyakunapruk, Thanida Auttapracha, Siwanart Kongarin
European Journal of Gastroenterology & Hepatology. 2025-02-01
Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021.
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Ethan Kai Jun Tham, Primrose Tothanarungroj, Thanida Auttapracha
Alcohol, Clinical & Experimental Research. 2025-02-01

Journal Articles

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.
Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5., American Journal of Gastrenterology, 6/8/2018
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances
Tsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature

Hot-Button Issues: Experts Share Opinions on Shifts in Clinical Innovation, Policy in 2024December 30th, 2024
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, the Liver Meeting®November 15th, 2024
Exploring FIB-4 for Fibrosis Risk AssessmentOctober 2nd, 2024
Join now to see all

Houston Methodist Hospitalhttps://www.houstonmethodist.org/doctor/mazen-noureddin/
Houston Research Institute https://www.houstonresearchinstitute.com/